Biomarker-driven combination treatment approach in non-clear cell RCC (Met-driven)

Author(s):

Dr. Laurence Albiges, MD, PhD, reviews the recent findings presented at the American Society of Clinical Oncology (ASCO) 2024 meeting, specifically focusing on the results of the phase 3 STELLAR trial.

EP: 1.Evolving Treatment Standards in Non-Clear Cell RCC

EP: 2.Extended Follow Up of KEYNOTE-B61

EP: 3.Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC

EP: 4.STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC

EP: 5.Case Presentation: 61-year-old male Renal Cell Carcinoma

EP: 6.Use of Combination Regimens in Frontline RCC

EP: 7.Treatment Decision Making in first-line combinations for advanced RCC

EP: 8.AE Management for Combination Regimens in Advanced RCC

EP: 9.AE Management for Combination Regimens in Advanced RCC

EP: 10.Optimizing Treatment in Advanced RCC

EP: 11.Dr Albiges Discusses a Non-Clear Cell RCC Patient Profile

EP: 12.Updates in the Treatment Approach for Non-clear cell RCC

EP: 13.Dr Albiges Reviews Long term follow up data from KEYNOTE-B61

EP: 14.Emerging Therapies in the Front-line Setting of Advanced non-clear cell RCC

Now Viewing

EP: 15.Biomarker-driven combination treatment approach in non-clear cell RCC (Met-driven)

Video content above is prompted by the following:

Please discuss the recent data presented at ASCO 2024 on the phase 3 STELLAR trial
Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study (Abstract TPS4611)